ATHENANCT07601295
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
StatusEnrolling by Invitation
PhasePhase 2
SponsorMarlene Rabinovitch, MD
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrolling by invitation only Show 4 more changesShow less
- Lead sponsor: Stanford University to Marlene Rabinovitch, MD
- Start date changed from estimate of Jul 2026 to Nov 4, 2026
- Eligibility criteria expanded, about 17 words
- Site details revised at 3 of 10 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in Pulmonary Vascular Resistance (PVR)
Timeframe: Baseline to week 24
Arms and interventions
Tiprelestat (5 mg)Experimental
Participants receive tiprelestat injection daily for 168 days.
Tiprelestat (10 mg)Experimental
Participants receive tiprelestat injection daily for 168 days.
Placebo (1 mL 0.9% saline solution)Placebo comparator
Participants receive placebo injection (matching tiprelestat) daily for 168 days.
Drugs: Tiprelestat (5 mg), Placebo (1 mL 0.9% saline solution), Tiprelestat (10 mg)
Sites
10 sites in 1 country